About brainstorm cell therapeutics inc - BCLI
Brainstorm Cell Therapeutics, Inc. is a biotechnology company, which develops and commercializes autologous cellular therapies for the treatment of neurodegenerative diseases, including Amyotrophic Lateral Sclerosis, Progressive Multiple Sclerosis, Alzheimer's disease, and other neurodegenerative diseases. Its pipeline, NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and improve neurological function. The company was founded by Irit Arbel on September 22, 2000 and is headquartered in New York, NY.
BCLI At a Glance
Brainstorm Cell Therapeutics, Inc.
1325 Avenue of Americas
New York, New York 10019
| Phone | 1-201-488-0460 | Revenue | 0.00 | |
| Industry | Biotechnology | Net Income | -10,307,000.00 | |
| Sector | Health Technology | Employees | 20 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
BCLI Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -0.643 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.187 |
BCLI Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -515,350.00 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
BCLI Liquidity
| Current Ratio | 0.028 |
| Quick Ratio | 0.028 |
| Cash Ratio | 0.003 |
BCLI Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -722.285 |
| Return on Equity | N/A |
| Return on Total Capital | 116.992 |
| Return on Invested Capital | N/A |
BCLI Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | -13.337 |
| Total Debt to Total Assets | 114.971 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | N/A |